CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 159 enrolled
Drug / intervention
LY3526318 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05086289
NCT05086289Phase 2Completed
CompareCT.gov

Randomized Placebo-controlled Phase 2 Clinical Trial to Evaluate LY3526318 for the Treatment of Chronic Low Back Pain

Eli Lilly and Company·interventional·Posted Oct 20, 2021·Updated Oct 5, 2023

In Brief

A Phase 2 clinical trial evaluating LY3526318 and Placebo for Chronic Low-back Pain. Completed, enrolled 159 participants across 31 sites in 2 countries.

Detailed Summary

The purpose of this study is to test whether LY3526318 is efficacious and safe in relieving chronic low back pain (CLBP). This trial is part of the chronic pain master protocol H0P-MC-CPMP (NCT05986292) which is a protocol to accelerate the development of new treatments for chronic pain.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Low-back Pain
CountriesPuerto Rico, United States
Collaborators--

Timeline

Phase 2CompletedFinished
20222023202420252026
First PostedOct 20, 2021
Enrollment StartOct 25, 2021
Primary CompletionJun 17, 2022
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 4.7 years ago

Interventions

LY3526318drug

Administered orally

Placebodrug

Administered orally